| Literature DB >> 26106476 |
Moi Lin Ling1, Yong Ming Tee1, Soong Geck Tan1, Ismawati M Amin1, Kue Bien How1, Kwee Yuen Tan1, Lai Chee Lee1.
Abstract
BACKGROUND: Carbapenem resistant Enterobacteriaceae (CRE) is increasingly reported worldwide. A similar increase is seen in Singapore since identification of its first case in 2008. The aim of this study was to identify local risk factors for carriage of CRE in patients from an acute tertiary care hospital in Singapore.Entities:
Keywords: Carbapenem resistant; Enterobacteriaceae; Epidemiology; Risk factors
Year: 2015 PMID: 26106476 PMCID: PMC4477303 DOI: 10.1186/s13756-015-0066-3
Source DB: PubMed Journal: Antimicrob Resist Infect Control ISSN: 2047-2994 Impact factor: 4.887
Demographic details of CRE patients and control patients
| Demographic | CP-CRE patients | Control | Standards | X-value |
|---|---|---|---|---|
| ( | ( | ( | ||
| n (%) | n (%) | n (%) | (case vs. standards) | |
| Mean age ± SD (years) | 64.3 ± 16.0 | 64.0 ± 15.7 | - | - |
| (mean years 95 % confidence interval) | (62.1–66.5) | (61.9–66.2) | ||
| Gender | ||||
| Male | 113 (55.7 %) | 113 (55.7 %) | 1,891,500 (49.2 %)[a] | 3.331 |
| Female | 90 (44.3 %) | 90 (44.3 %) | 1,953,200 (50.8 %)[a] | (0.068) |
| Paying class | ||||
| (based on collection ward) | ||||
| Class A | 16 (7.9 %) | 26 (12.8 %) | 5696 (7.2 %)[b] | |
| Class B1/B1+ | 20 (9.9 %) | 15 (7.4 %) | 9050 (11.5 %)[b] | 9.086 |
| Class B2 | 86 (42.4 %) | 77 (37.9 %) | 32,048 (40.8 %)[b] | (0.028)* |
| Class C | 81 (39.9 %) | 85 (41.9 %) | 24,028 (30.6 %)[b] | |
| Ethnic group | ||||
| Chinese | 134 (66.0 %) | 133 (72.7 %) | 2,853,800 (74.2 %)[a] | |
| Malay | 29 (14.3 %) | 32 (17.5 %) | 512,800 (13.3 %)[a] | 5.437 |
| Indian | 16 (7.9 %) | 16 (8.7 %) | 351,700 (9.1 %)[a] | (0.142) |
| Others (Singaporean) | 1 (0.5 %) | 2 (1.1 %) | 126,500 (3.3 %)[a] | |
| Others: Bangladeshi | 7 (3.4 %) | 1 (0.5 %) | - | - |
| Others: Burmese | 1 (0.5 %) | 1 (0.5 %) | - | - |
| Others: Chinese | 1 (0.5 %) | 4 (1.9 %) | - | - |
| Others: Indian | 2 (1.0 %) | 2 (1.0 %) | - | - |
| Others: Indonesian | 4 (1.9 %) | 4 (1.9 %) | - | - |
| Others: Malaysian | 2 (1.0 %) | 0 (0 %) | ||
| Others: Oman | 1 (0.5 %) | 0 (0 %) | ||
| Others: Pakistani | 2 (1.0 %) | 0 (0 %) | ||
| Others: Qatar | 0 (0 %) | 1 (0.5 %) | - | - |
| Others: Thai | 0 (0 %) | 1 (0.5 %) | - | - |
| Others: UAE | 0 (0 %) | 2 (1.0 %) | ||
| Others: Vietnamese | 3 (1.5 %) | 3 (1.5 %) | - | - |
*p < 0.05 (Significance of association; 2-tailed)
aDepartment of Statistics Singapore, 2013, Population Trends 2013
bSGH Bulletin Beds in Service by Ward and Bed Class (2013)
Fig. 1Distribution of CRE by isolation sites
Fig. 2Carbapenemase types isolated
Univariate analysis of risk factors associated with CRE carriage
| Risk factors | CP-CRE patients | Control | X = value/Mann-Whitney U | Odds Ratio |
|---|---|---|---|---|
| ( | ( | ( | [95 % Cl] | |
| n (%) | n (%) | |||
| Total length of stay ± SD | 48.0 ± 59.5 | 3.9 ± 3 8 | U: 3223 | 1.266 [1.197–1.340] |
| (days) | (39.8–56.3) | (3.4–4.5) | (<0.001) | (<0.001) |
| (moan days 95 % confidence interval) | ||||
| History of previous overseas hospitalisation | 29 (14.3 %) | 1 (0.5 %) | 28.218 (<0.001)** | 33.667 [4.539–259.700] |
| History of travelling in past 90 days | 29 (14.3 %) | 15 7.4 %) | 4.996 (0.025)* | 2.089 [10.83.4.028] |
| Ambulant on arrival | 103 (50.7 %) | 153 (75.4 %) | 26.432 (<0.001)** | 0.337 [0.221–0.513] |
| Admission to CU | 54 (26.6 %) | 6 (3.0 %) | 45.059 (<0.001)** | 11.899 [4.986–28.399] |
| Mean ICU stay ± SD, day | 9.6 ± 12.2 | 1.2 ± 1.0 |
| - |
| (mean days 95 % confidence interval) | (6.3—13.0) | (0.1—2.2) | ||
| Admission to HD/ICA | 106 (52.2 %) | 29 (14.3 %) | 65.797 (<0.001)** | 6.557 [4.057–10.596] |
| Mean HD/ICA stay ± SD, day | 5.3 ± 6.1 | 2.0 ± 1.7 | 9.0 (0.372) | - |
| (mean days 95 % confidence interval) | (4.1–6.5) | (1.4–2.7) | ||
| Cardiovascular disease comorbidity | 105 (51.7 %) | 74 (36.5 %) | 9.602 (0.002)** | 1.868 [1.256–2.778] |
| Diabetes mellitus comorbidity | 67 (33.0 %) | 58 (28.6 %) | 0.936 (0.333) | 1.232 [0.807–1.870] |
| Malignancy cormorbidity | 57 (28.1 %) | 41 (20.2 %) | 3.443 (0.064) | 1.543 [0.974–2.442] |
| Immunodeficiency comorbidity | 10 (4.9 %) | 2 (1.0 %) | 5.496 (0.019)* | 5.207 [1.126–24.072] |
| Haematology comorbidity | 20 (9.9 %) | 5 (2.5 %) | 9.591 (0.002)** | 4.328 [1.592–11.769] |
| Exposure to DXT | 23 (11.3 %) | 11 (5.4 %) | 4.622 (0.032)* | 2.230 [1.057–4.706] |
| Exposure to steroid | 34 (16.7 %) | 12 (5.9 %) | 11.866 (0.001)** | 3.202 [1.606–6.384] |
| Exposure to chemotherapy | 15 (7.4 %) | 16 (7.9 %) | 0.035 (0.852) | 0.933 [0.448–1.941] |
| Exposure to penicillin antibiotics | 33 (16 3 %) | 7 (3.4 %) | 18.747 (<0.001)** | 5.435 [2.344–12.604] |
| Exposure to β-lactam/β-lactamase inhibitor combinations antibiotics | 122 (60.1 %) | 59 (29.1 %) | 39.568 (<0.001)** | 3.676 [2.432–5.557] |
| Exposure to cephalosporin antibiotics | 65 (32.0 %) | 43 (21.2 %) | 6.106 (0.013)* | 1.753 [1.120–2.742] |
| Exposure to carbapenems antibiotics | 62 (30.5 %) | 5 (2.5 %) | 58.077 (<0.001)** | 17.413 [6.826–44.417] |
| Exposure to fluoroquinolones antibiotics | 35 (17.2 %) | 19 (9.4 %) | 5.468 (0.019)* | 2.018 [1.111–3.663] |
| Exposure to glycopeptide antibiotics | 69 (34.0 %) | 4 (2.0 %) | 70.564 (<0001)** | 25.618 [9.132–71.865] |
| Exposure to metronidazole antibiotics | 36 (17.7 %) | 15 (7.4 %) | 9.889 (0.002)** | 2.702 [1.428–5.110] |
| Exposure to aminoglycosides antibiotics | 17 (8.4 %) | 1 (0.5 %) | 14.882 (<0.001)** | 18.462 [2433–140,097] |
| Presence of central line device | 80 (39.4 %) | 11 (5.4 %) | 67.433 (<0.001)** | 11.353 [5.811–22.179] |
| Presence of urinary catheter device | 86 (42.4 %) | 30 (14.8 %) | 37.842 (<0.001)** | 4.239 [2.630–6.831] |
| Presence of ETT device | 42 (20.7 %) | 6 (3.0 %) | 30.620 (<0.001)** | 8.565 [3.55 1–20.658] |
| Presence of intra-arterial line device | 24 (11.8 %) | 5 (2.5 %) | 13.406 (<0.001)** | 5.309 [1.984–14.2 11] |
| Presence of drains device | 31 (15.3 %) | 11 (5.4 %) | 10.623 (0.001)** | 3.146 [1.534–6.450] |
| Presence of enteral feeding device | 49 (24.1 %) | 11 (5.4 %) | 28.240 (<0.001)** | 5.554 [2.793–11.044] |
| Presence of additional MRSA | 47 (23.2 %) | 26 (12.8 %) | 7.365 (0.007)** | 2.051 [1.213–3.468] |
| Presence of additional VRE | 32 (15.8 %) | 5 (2.5 %) | 21.678 (<0.001)** | 7.411 [2.825-19.441] |
| Exposure to bronchoscopy procedure | 22 (10.8 %) | 4 (2.0 %) | 13.314 (<0.001)** | 6.047 [2.045–17.881] |
| Exposure to gastroscopy procedure | 18 (8.9 %) | 10 (4.9 %) | 2.455 (0.117) | 1.878 [0.845–4.175] |
| Exposure to colonoscopy procedure | 4 (2.0 %) | 6 (3.0 %) | 0.410 (0.522) | 0.660 [0.183–2.375] |
| Exposure to angiogram procedure | 9 (4.4 %) | 6 (3.0 %) | 0.623 (0.430) | 1.523 [0.532–4361] |
| Underwent surgery | 141 (69.5 %) | 146 (71.9 %) | 0.297 (0.586) | 1.126 [0.734–1.727] |
*p < 0.05 (Significance of association; 2-tailed), **p < 0.01 (Significance of association; 2-tailed)
Multivariate analysis of risk factors
| Risk factor (Multivariable model) | Adjusted Odds Ratio |
|---|---|
| [95 % Confidence Interval] | |
| (Sig) | |
| Exposure to antibiotics penicillin | 4.640 [1.529–14.079] (0.007)* |
| Exposure to antibiotics glycopeptides | 5.162 [1.377–19.346] (0.015)** |
| Presence of central line device | 3.117 [1.167–8.330] (0.023)** |
*p < 0.01; **p < 0.05 (Significance of association; 2-tailed)